EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review

María Antonia Pérez-Moreno iD, Pablo Ciudad-Gutiérrez, Didiana Jaramillo-Ruiz, Juan Luis Reguera-Ortega, Laila Abdel-Kader Martín, Sandra Flores-Moreno

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241914780 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von María Antonia Pérez-Moreno und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University Hospital Virgen del Rocío, 41013 Seville, Spain. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this paper was to review the available evidence on the efficacy and safety of combined or sequential use of PD-1/PD-L1 immune checkpoint inhibitors (ICI) and CAR-T cell therapies in relapsed/refractory (R/R) haematological malignancies. A systematic literature review was performed until 21 November 2022. Inclusion criteria: cohort studies/clinical trials aimed at evaluating the efficacy and/or safety of the combination of CAR-T cell therapy with PD-1/PD-L1 inhibitors in R/R haematological malignancies, which had reported results. Those focusing only on ICI or CAR-T separately or evaluating the combination in other non-hematological solid tumours were excluded. We used a specific checklist for quality assessment of the studies, and then we extracted data on efficacy or efficiency and safety. A total of 1867 articles were identified, and 9 articles were finally included (early phase studies, with small samples of patients and acceptable quality). The main pathologies were B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin’s lymphoma (B-NHL). The most studied combination was tisagenlecleucel with pembrolizumab. In terms of efficacy, there is great variability: the combination could be a promising option in B-ALL, with modest data, and in B-NHL, although hopeful responses were received, the combination does not appear better than CAR-T cell monotherapy. The safety profile could be considered comparable to that described for CAR-T cell monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematologic NeoplasmsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalImmunotherapy, AdoptiveT-Lymphocytes

Stichwörter der Autor:innen

checkpoint inhibitorschimeric antigen receptor-Tcombined therapyhaematologic tumoursystematic review

Substanzen

Immune Checkpoint InhibitorsReceptors, Chimeric AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Pharmacy, University Hospital Virgen del Rocío, 41013 Seville, Spain.
  • Department of Haematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, University of Seville, 41012 Seville, Spain.
  • Department of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.

ORCID-Profile: María Antonia Pérez-Moreno

Zitieren

APA

Pérez-Moreno, M. A., Ciudad-Gutiérrez, P., Jaramillo-Ruiz, D., Reguera-Ortega, J. L., Abdel-Kader Martín, L., & Flores-Moreno, S. (2023). Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914780

Vancouver

Pérez-Moreno MA, Ciudad-Gutiérrez P, Jaramillo-Ruiz D, Reguera-Ortega JL, Abdel-Kader Martín L, Flores-Moreno S. Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914780

BibTeX
@article{PrezMoreno2023,
  author = {Pérez-Moreno, María Antonia and Ciudad-Gutiérrez, Pablo and Jaramillo-Ruiz, Didiana and Reguera-Ortega, Juan Luis and Abdel-Kader Martín, Laila and Flores-Moreno, Sandra},
  title = {Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241914780}
}
Kostenlos starten →